A method for the construction of both rigid and compliant (flexible) transparent flow phantoms of biological flow structures, suitable for PIV and other optical flow methods with refractive-index-matched working fluid is described in detail. Methods for matching the in vivo compliance and elastic wave propagation wavelength are presented. The manipulation of MRI and CT scan data through an investment casting mould is described. A method for the casting of bubble-free phantoms in silicone elastomer is given. The method is applied to fabricate flexible phantoms of the carotid artery (with and without stenosis), the carotid artery bifurcation (idealised and patient-specific) and the human upper airway (nasal cavity). The fidelity of the phantoms to the original scan data is measured, and it is shown that the cross-sectional error is less than 5% for phantoms of simple shape but up to 16% for complex cross-sectional shapes such as the nasal cavity. This error is mainly due to the application of a PVA coating to the inner mould and can be reduced by shrinking the digital model. Sixteen per cent variation in area is less than the natural patient to patient variation of the physiological geometries. The compliance of the phantom walls is controlled within physiologically realistic ranges, by choice of the wall thickness, transmural pressure and Young's modulus of the elastomer. Data for the dependence of Young's modulus on curing temperature are given for Sylgard 184. Data for the temperature dependence of density, viscosity and refractive index of the refractiveindex-matched working liquid (i.e. water-glycerol mixtures) are also presented.

No abstract

No abstract

Bloodstain Pattern Analysis is a forensic discipline in which, among others, the position of victims can be determined at crime scenes on which blood has been shed. To determine where the blood source was investigators use a straight-line approximation for the trajectory, ignoring effects of gravity and drag and thus overestimating the height of the source. We determined how accurately the location of the origin can be estimated when including gravity and drag into the trajectory reconstruction. We created eight bloodstain patterns at one meter distance from the wall. The origin’s location was determined for each pattern with: the straight-line approximation, our method including gravity, and our method including both gravity and drag. The latter two methods require the volume and impact velocity of each bloodstain, which we are able to determine with a 3D scanner and advanced fluid dynamics, respectively. We conclude that by including gravity and drag in the trajectory calculation, the origin’s location can be determined roughly four times more accurately than with the straight-line approximation. Our study enables investigators to determine if the victim was sitting or standing, or it might be possible to connect wounds on the body to specific patterns, which is important for crime scene reconstruction.

No abstract

No abstract

Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the western world. In the last three decades, fluid dynamics investigations have been an important component in the study of the cardiovascular system and CVD. A large proportion of studies have been restricted to computational fluid dynamic (CFD) modeling of blood flow. However, with the development of flow measurement techniques such as particle image velocimetry (PIV), and recent advances in additive manufacturing, experimental investigation of such flow systems has become of interest to validate CFD studies, testing vascular implants and using the data for therapeutic procedures. This article reviews the technical aspects of in-vitro arterial flow measurement with the focus on PIV. CAD modeling of geometries and rapid prototyping of molds has been reviewed. Different processes of casting rigid and compliant models for experimental analysis have been reviewed and the accuracy of construction of each method has been compared. A review of refractive index matching and blood mimicking flow circuits is also provided. Methodologies and results of the most influential experimental studies are compared to elucidate the benefits, accuracy and limitations of each method.

Background Nasal High Flow (NHF) therapy delivers flows of heated humidified gases up to 60 LPM (litres per minute) via a nasal cannula. Particles of oral/nasal fluid released by patients undergoing NHF therapy may pose a cross-infection risk, which is a potential concern for treating COVID-19 patients. Methods Liquid particles within the exhaled breath of healthy participants were measured with two protocols: (1) high speed camera imaging and counting exhaled particles under high magnification (6 participants) and (2) measuring the deposition of a chemical marker (riboflavin-5-monophosphate) at a distance of 100 and 500 mm on filter papers through which air was drawn (10 participants). The filter papers were assayed with HPLC. Breathing conditions tested included quiet (resting) breathing and vigorous breathing (which here means nasal snorting, voluntary coughing and voluntary sneezing). Unsupported (natural) breathing and NHF at 30 and 60 LPM were compared. Results Imaging: During quiet breathing, no particles were recorded with unsupported breathing or 30 LPM NHF (detection limit for single particles 33 μm). Particles were detected from 2 of 6 participants at 60 LPM quiet breathing at approximately 10% of the rate caused by unsupported vigorous breathing. Unsupported vigorous breathing released the greatest numbers of particles. Vigorous breathing with NHF at 60 LPM, released half the number of particles compared to vigorous breathing without NHF. Chemical marker tests: No oral/nasal fluid was detected in quiet breathing without NHF (detection limit 0.28 μL/m3). In quiet breathing with NHF at 60 LPM, small quantities were detected in 4 out of 29 quiet breathing tests, not exceeding 17 μL/m3. Vigorous breathing released 200–1000 times more fluid than the quiet breathing with NHF. The quantities detected in vigorous breathing were similar whether using NHF or not. Conclusion During quiet breathing, 60 LPM NHF therapy may cause oral/nasal fluid to be released as particles, at levels of tens of μL per cubic metre of air. Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing (p < 0.001 with both imaging and chemical marker methods). During vigorous breathing, 60 LPM NHF therapy caused no statistically significant difference in the quantity of oral/nasal fluid released compared to unsupported breathing. NHF use does not increase the risk of dispersing infectious aerosols above the risk of unsupported vigorous breathing. Standard infection prevention and control measures should apply when dealing with a patient who has an acute respiratory infection, independent of which, if any, respiratory support is being used. Clinical trial registration ACTRN12614000924651